Detecting gastrointestinal manifestations in patients with systemic sclerosis using anti-gAChR antibodies

Nakane, Shunya; Umeda, Masataka; Kawashiri, Shin-ya; Mukaino, Akihiro; Ichinose, Kunihiro; Higuchi, Osamu; Maeda, Yasuhiro; Nakamura, Hideki; Matsuo, Hidenori; Kawakami, Atsushi

doi:10.1186/s13075-020-2128-z

Arthritis Research & Therapy

Table 2 Summary of the characteristics of 19 patients with SSc and GI manifestations

From: Detecting gastrointestinal manifestations in patients with systemic sclerosis using anti-gAChR antibodies

Patient no. (years, sex)	SSc duration, years	Anti-gAChR Abs	Levels of anti-gAChR Abs ^a, α3/β4	Other Abs	Complications	Type of SSc	Clinical features (RP, DU, RC, IP, PH)	GI manifestation (GERD, PI, C, D, and other symptoms ^b)
1 (76, F)	3	Positive (α3)	3.607 (+)/0.212 (−)	Scl-70	RA	Diffuse	RP, DU, IP	C, D
2 (57, F)	4	Positive (α3, β4)	2.694 (+)/1.766 (+)	ACA		Limited	RP	GERD
3 (64, F)	12	Positive (α3)	1.200 (+)/0.516 (−)	RNP	SS	Diffuse	RP, PH	GERD
4 (63, M)	0	Positive (α3)	1.025 (+)/0.838 (−)	(Negative)	PM	Diffuse	RP, RC, IP	GERD, appetite loss, nausea/vomiting, early satiety, PI, C
5 (57, F)	3	Negative	0.420 (−)/0.248 (−)	ACA	SS, PBC	Limited	RP	GERD, C
6 (75, F)	2	Negative	0.431 (−)/0.272 (−)	Scl-70	SS	Diffuse	RP, DU, RC, IP	Appetite loss
7 (64, F)	0	Negative	0.817 (−)/0.482 (−)	ACA	Chronic thyroiditis	Limited	RP, IP	GERD
8 (63, F)	26	Negative	0.368 (−)/0.207 (−)	ARS		Limited	RP, IP	Appetite loss, C
9 (61, F)	22	Negative	0.499 (−)/0.582 (−)	Scl-70		Diffuse	RP, DU, IP	GERD, appetite loss, C
10 (63, F)	18	Negative	0.354 (−)/0.209 (−)	Scl-70	GPA, RA	Diffuse	RP, IP	GERD, appetite loss, nausea/vomiting, C
11 (49, F)	10	Negative	0.306 (−)/0.325 (−)	ACA	SS	Limited	RP	GERD, appetite loss
12 (66, F)	4	Negative	0.309 (−)/0.242 (−)	ACA		Limited	RP	C
13 (44, F)	7	Negative	0.350 (−)/0.255 (−)	Scl-70	Chronic thyroiditis	Diffuse	RP, DU	GERD
14 (68, F)	3	Negative	0.271 (−)/0.277 (−)	ACA		Limited	RP	GERD
15 (66, F)	10	Negative	0.436 (−)/0.420 (−)	Scl-70		Diffuse	RP, DU, IP	GERD, appetite loss
16 (63, F)	2	Negative	0.416 (−)/0.253 (−)	ACA		Limited	RP	Appetite loss, nausea/vomiting, early satiety, C
17 (69, F)	6	Negative	0.540 (−)/0.355 (−)	(Negative)		Limited	RP, DU, PH	GERD
18 (51, F)	2	Negative	0.334 (−)/0.336 (−)	ACA	Chronic thyroiditis	Limited	RP	GERD, C
19 (60, F)	2	Negative	0.271 (−)/0.253 (−)	(Negative)		Diffuse	RP	GERD, appetite loss, nausea/ vomiting, early satiety, C

Abbreviations: Abs autoantibodies, ACA anti-centromere antibodies, ARS anti-aminoacyl-tRNA synthetase antibodies, C constipation, D diarrhea, DU digital ulcers, F female, gAChR ganglionic acetylcholine receptor, GERD gastroesophageal reflux disease, GI gastrointestinal, GPA granulomatosis with polyangiitis, IP interstitial pneumonitis, M male, PBC primary biliary cirrhosis, PH pulmonary hypertension, PI paralytic ileus, PM polymyositis, RA rheumatoid arthritis, RC renal crisis, RP Raynaud’s phenomenon, SS Sjögren’s syndrome, SSc systemic sclerosis
^aThe normal value of gAChR Abs established from healthy individuals was < 1.0 AI
^bOther GI manifestations of symptoms included appetite loss, nausea/vomiting, early satiety, and postprandial abdominal pain associated with dysfunction of the upper digestive system

Back to article page

ISSN: 1478-6362

Contact us

General enquiries: journalsubmissions@springernature.com